Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine

Executive Summary

Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.

You may also be interested in...



Ligand Adds New Expertise, Revenue Potential With Pfenex Buyout

Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Torrent Charts Gains From Unichem Acquisition, More In Store

Torrent Pharma has made “substantial progress” with the integration of the acquired Unichem business, turning around key brands and building momentum in field force productivity. Rationalization efforts are expected to drive additional cost savings going forward.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel